A Phase 2 interventional study of DOR/ISL in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 17 sites in 5 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2024-01-31.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 2, single-group, multi-site, open-label study of an islatravir/doravirine (ISL/DOR, MK-8591A) fixed dose combination (FDC) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric participants who are virologically suppressed (VS) on antiretroviral therapy (ART) for ≥3 months or are treatment-naive (TN). The primary purposes of the study are 1) to examine the steady-state pharmacokinetics (PK) of ISL in plasma; 2) the steady-state PK of ISL-triphosphate (ISL-TP) in peripheral blood mononuclear cells (PBMCs); and 3) to examine the safety and tolerability of ISL/DOR.
As of protocol amendment 03 (approved 08-Feb-2022), all participants have been discontinued from study therapy and will be switched to non-study antiretroviral therapy and monitored for safety. The present results cover data obtained through the cut-off date of 30-Mar-2022, and will be updated once monitoring is completed.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric participants with HIV-1 infection receive DOR/ISL for 96 weeks.
Drug: DOR/ISL
Drug pages: Doravirine · Islatravir
100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
Also known as: MK-8591A, Doravirine/islatravir
Area Under the Plasma Drug Concentration-time Curve From 0 to 24 Hours Post-dose (AUC0-24) of Islatravir (ISL)
The AUC0-24 of ISL in plasma was determined at steady state.
Time frame: Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28
Maximum Plasma Concentration (Cmax) of ISL
The Cmax of ISL in plasma was determined at steady state.
Time frame: Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28
Time to Reach Maximum Plasma Concentration (Tmax) of ISL
The Tmax of ISL in plasma was determined at steady state.
Time frame: Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28
Apparent Plasma Terminal Half-life (t½) of ISL
The t½ of ISL in plasma was determined at steady state.
Time frame: Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28
Apparent Total Clearance From Plasma (CL/F) of ISL
The CL/F of ISL from plasma was determined at steady state.
Time frame: Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28
Apparent Volume of Distribution During Terminal Phase (Vz/F) of ISL
The Vz/F of ISL was determined at steady state.
Time frame: Pre-dose, and 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose on Day 28
AUC0-last of ISL-triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMCs)
The AUC0-24 of ISL-TP in PBMCs was determined at steady state.
Time frame: Pre-dose, and 4 and 24 hours post-dose on Day 28
Cmax of ISL-TP in PBMCs
The Cmax of ISL-TP in PBMCs was determined at steady state.
Time frame: Pre-dose, and 4, and 24 hours post-dose on Day 28
C24 of ISL-TP in PBMCs
The C24 of ISL-TP in PBMCs was determined at steady state.
Time frame: 24 hours post-dose on Day 28
Number of Participants Experiencing ≥1 Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 24 weeks
Number of Participants Discontinuing From Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 24 weeks
Percentage of Virologically Suppressed (VS) Participants With HIV-1 Ribonucleic Acid (RNA) ≥50 Copies/mL
The percentage of VS participants with HIV-1 RNA ≥50 copies/mL was determined at the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay with a lower limit of detection (LLOD) of 40 copies/mL.
Time frame: Week 24
Percentage of VS Participants With HIV-1 RNA <50 Copies/mL
The percentage of VS participants with HIV-1 RNA \<50 copies/mL will be determined at the central laboratory with an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.
Time frame: Week 24
Percentage of Treatment Naive (TN) Participants With HIV-1 RNA <50 Copies/mL
The percentage of TN participants with HIV-1 RNA \<50 copies/mL will be determined at the central laboratory with an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.
Time frame: Week 24
Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-cells in VS Participants
CD4+ T-cell counts were measured by a central laboratory. Negative and positive results represent a decrease and increase, respectively, from baseline CD4+ T-cell counts.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in CD4+ T-cells in TN Participants
CD4+ T-cell counts were measured by a central laboratory. Negative and positive results represent a decrease and increase, respectively, from baseline CD4+ T-cell counts.
Time frame: Baseline (Day 1) and Week 24
Incidence of Viral Drug Resistance to DOR
The number of participants with viral drug resistance to DOR was determined.
Time frame: Up to 24 weeks
Incidence of Viral Drug Resistance to ISL
The number of participants with viral drug resistance to ISL was determined.
Time frame: Up to 24 weeks
Palatability of DOR/ISL Tablet
The palatability of the DOR/ISL tablet (whole or split) was assessed with a modified 5-point facial hedonic scale. Responses ranged from 1 ("very bad") to 5 ("very good"). Data show the number of VS and TN participants responding at each score at the designated time points.
Time frame: Baseline (Day 1), Week 4, and Week 24
Acceptability of DOR/ISL Tablet
The acceptability of the DOR/ISL tablet (whole or split) was assessed. Acceptability was assessed by monitoring for refusing the tablet, throwing up or spitting out the tablet, and gagging on the tablet. Data show the number of VS and TN participants responding at each score at the designated time points.
Time frame: Baseline (Day 1), Week 4, and Week 24
Pediatric participants who were ≥35 kg body weight and \<18 years of age were recruited at 18 study sites located in Italy, Russian Federation, Thailand, South Africa, and the United States.
| Milestone | DOR/ISL: Virologically Suppressed Cohort | DOR/ISL: Treatment Naive Cohort |
|---|---|---|
| Started | 39 | 3 |
| Completed | 22 | 2 |
| Not completed | 17 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Ongoing for safety monitoring | 14 | 1 |
| Withdrew: Excluded from results due to informed consent issue | 2 | 0 |
The AUC0-24 of ISL in plasma was determined at steady state.
| hr*µmol/L | DOR/ISL: Virologically Suppressed Cohort |
|---|---|
| Area Under the Plasma Drug Concentration-time Curve From 0 to 24 Hours Post-dose (AUC0-24) of Islatravir (ISL) | 0.114 ± 28.6 |
The Cmax of ISL in plasma was determined at steady state.
| µmol/L | DOR/ISL: Virologically Suppressed Cohort |
|---|---|
| Maximum Plasma Concentration (Cmax) of ISL | 0.0245 ± 53.4 |
The Tmax of ISL in plasma was determined at steady state.
| hours | DOR/ISL: Virologically Suppressed Cohort |
|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of ISL | 1.00 (0.50 to 4.00) |
The t½ of ISL in plasma was determined at steady state.
| hours | DOR/ISL: Virologically Suppressed Cohort |
|---|---|
| Apparent Plasma Terminal Half-life (t½) of ISL | 16.5 ± 70.0 |
The CL/F of ISL from plasma was determined at steady state.
| L/hr | DOR/ISL: Virologically Suppressed Cohort |
|---|---|
| Apparent Total Clearance From Plasma (CL/F) of ISL | 22.5 ± 28.6 |
The Vz/F of ISL was determined at steady state.
| Liters | DOR/ISL: Virologically Suppressed Cohort |
|---|---|
| Apparent Volume of Distribution During Terminal Phase (Vz/F) of ISL | 536 ± 61.1 |
The AUC0-24 of ISL-TP in PBMCs was determined at steady state.
| hr*pmol/10^6 cells | DOR/ISL: Virologically Suppressed Cohort |
|---|---|
| AUC0-last of ISL-triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMCs) | 52.3 ± 74.9 |
The Cmax of ISL-TP in PBMCs was determined at steady state.
| pmol/10^6 cells | DOR/ISL: Virologically Suppressed Cohort |
|---|---|
| Cmax of ISL-TP in PBMCs | 2.87 ± 91.6 |
The C24 of ISL-TP in PBMCs was determined at steady state.
| pmol/10^6 cells | DOR/ISL: Virologically Suppressed Cohort |
|---|---|
| C24 of ISL-TP in PBMCs | 2.05 ± 71.7 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | DOR/ISL: Virologically Suppressed Cohort | DOR/ISL: Treatment Naive Cohort |
|---|---|---|
| Number of Participants Experiencing ≥1 Adverse Event (AE) | 21 | 2 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | DOR/ISL: Virologically Suppressed Cohort | DOR/ISL: Treatment Naive Cohort |
|---|---|---|
| Number of Participants Discontinuing From Study Treatment Due to an AE | 0 | 0 |
The percentage of VS participants with HIV-1 RNA ≥50 copies/mL was determined at the central laboratory with an Abbott Real Time Polymerase Chain Reaction (PCR) assay with a lower limit of detection (LLOD) of 40 copies/mL.
| percentage of participants | DOR/ISL: Virologically Suppressed Cohort |
|---|---|
| Percentage of Virologically Suppressed (VS) Participants With HIV-1 Ribonucleic Acid (RNA) ≥50 Copies/mL | 2.9 (0.1 to 15.3) |
The percentage of VS participants with HIV-1 RNA \<50 copies/mL will be determined at the central laboratory with an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.
| percentage of participants | DOR/ISL: Virologically Suppressed Cohort |
|---|---|
| Percentage of VS Participants With HIV-1 RNA <50 Copies/mL | 94.1 (80.3 to 99.3) |
The percentage of TN participants with HIV-1 RNA \<50 copies/mL will be determined at the central laboratory with an Abbott Real Time PCR assay with a LLOD of 40 copies/mL.
| percentage of participants | DOR/ISL: Treatment Naive Cohort |
|---|---|
| Percentage of Treatment Naive (TN) Participants With HIV-1 RNA <50 Copies/mL | 100.0 (2.5 to 100.0) |
CD4+ T-cell counts were measured by a central laboratory. Negative and positive results represent a decrease and increase, respectively, from baseline CD4+ T-cell counts.
| cells/mm^3 | DOR/ISL: Virologically Suppressed Cohort |
|---|---|
| Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-cells in VS Participants | -112.1 (-175.8 to -48.4) |
CD4+ T-cell counts were measured by a central laboratory. Negative and positive results represent a decrease and increase, respectively, from baseline CD4+ T-cell counts.
| cells/mm^3 | DOR/ISL: Treatment Naive Cohort |
|---|---|
| Change From Baseline in CD4+ T-cells in TN Participants | 705.0 (NA to NA) |
The number of participants with viral drug resistance to DOR was determined.
| Participants | DOR/ISL: Virologically Suppressed Cohort | DOR/ISL: Treatment Naive Cohort |
|---|---|---|
| Incidence of Viral Drug Resistance to DOR | 0 | 0 |
The number of participants with viral drug resistance to ISL was determined.
| Participants | DOR/ISL: Virologically Suppressed Cohort | DOR/ISL: Treatment Naive Cohort |
|---|---|---|
| Incidence of Viral Drug Resistance to ISL | 0 | 0 |
The palatability of the DOR/ISL tablet (whole or split) was assessed with a modified 5-point facial hedonic scale. Responses ranged from 1 ("very bad") to 5 ("very good"). Data show the number of VS and TN participants responding at each score at the designated time points.
| Participants | DOR/ISL: Virologically Suppressed Cohort | DOR/ISL: Treatment Naive Cohort |
|---|---|---|
| Very Bad - Day 1 | 0 | 0 |
| Very Bad - Week 4 | 0 | 0 |
| Very Bad - Week 24 | 2 | 0 |
| Bad - Day 1 | 0 | 0 |
| Bad - Week 4 | 0 | 0 |
| Bad - Week 24 | 3 | 0 |
| Neither good or bad - Day 1 | 12 | 0 |
| Neither good or bad - Week 4 | 11 | 0 |
| Neither good or bad - Week 24 | 8 | 0 |
| Good - Day 1 | 9 | 2 |
| Good - Week 4 | 11 | 2 |
| Good - Week 24 | 5 | 1 |
| Very Good - Day 1 | 16 | 1 |
| Very Good - Week 4 | 15 | 1 |
| Very Good - Week 24 | 4 | 0 |
The acceptability of the DOR/ISL tablet (whole or split) was assessed. Acceptability was assessed by monitoring for refusing the tablet, throwing up or spitting out the tablet, and gagging on the tablet. Data show the number of VS and TN participants responding at each score at the designated time points.
| Participants | DOR/ISL: Virologically Suppressed Cohort | DOR/ISL: Treatment Naive Cohort |
|---|---|---|
| Refusing - Day 1 | 0 | 0 |
| Refusing - Week 4 | 0 | 0 |
| Refusing - Week 24 | 0 | 0 |
| Throwing Up/Spitting Out - Day 1 | 0 | 0 |
| Throwing Up/Spitting Out - Week 4 | 0 | 0 |
| Throwing Up/Spitting Out - Week 24 | 0 | 0 |
| Gagging - Day 1 | 0 | 0 |
| Gagging - Week 4 | 0 | 0 |
| Gagging - Week 24 | 1 | 0 |
Collected over Up to approximately 16 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DOR/ISL: Virologically Suppressed Cohort | 0/37 (0%) | 1/37 (2.7%) | 13/37 (35.1%) |
| DOR/ISL: Treatment Naive Cohort | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| DOR/ISL: Virologically Suppressed Cohort Extended Monitoring | 0/14 (0%) | 0/14 (0%) | 12/14 (85.7%) |
| DOR/ISL: Treatment Naive Cohort Extended Monitoring | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | DOR/ISL: Virologically Suppressed Cohort | DOR/ISL: Treatment Naive Cohort | DOR/ISL: Virologically Suppressed Cohort Extended Monitoring | DOR/ISL: Treatment Naive Cohort Extended Monitoring |
|---|---|---|---|---|
| ConcussionInjury, poisoning and procedural complications | 1/37 | 0/3 | 0/14 | 0/1 |
| Event | DOR/ISL: Virologically Suppressed Cohort | DOR/ISL: Treatment Naive Cohort | DOR/ISL: Virologically Suppressed Cohort Extended Monitoring | DOR/ISL: Treatment Naive Cohort Extended Monitoring |
|---|---|---|---|---|
| COVID-19Infections and infestations | 0/37 | 0/3 | 1/14 | 1/1 |
| DyspepsiaGastrointestinal disorders | 0/37 | 1/3 | 0/14 | 0/1 |
| PyrexiaGeneral disorders | 2/37 | 1/3 | 1/14 | 0/1 |
| Vaccination site painGeneral disorders | 1/37 | 1/3 | 1/14 | 0/1 |
| DizzinessNervous system disorders | 2/37 | 1/3 | 1/14 | 0/1 |
| HeadacheNervous system disorders | 2/37 | 1/3 | 1/14 | 0/1 |
| UrticariaSkin and subcutaneous tissue disorders | 0/37 | 1/3 | 0/14 | 0/1 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/37 | 0/3 | 4/14 | 0/1 |
| Upper respiratory tract infectionInfections and infestations | 3/37 | 0/3 | 3/14 | 0/1 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 4/37 | 0/3 | 3/14 | 0/1 |
| Age, Continuous(years) | DOR/ISL: Virologically Suppressed Cohort | DOR/ISL: Treatment Naive Cohort | Total |
|---|---|---|---|
| Mean | 14.7 ± 2.2 | 15.7 ± 1.5 | 14.8 ± 2.1 |
| Sex: Female, Male(Participants) | DOR/ISL: Virologically Suppressed Cohort | DOR/ISL: Treatment Naive Cohort | Total |
|---|---|---|---|
| Female | 14 | 1 | 15 |
| Male | 23 | 2 | 25 |
| Ethnicity (NIH/OMB)(Participants) | DOR/ISL: Virologically Suppressed Cohort | DOR/ISL: Treatment Naive Cohort | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 35 | 3 | 38 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | DOR/ISL: Virologically Suppressed Cohort | DOR/ISL: Treatment Naive Cohort | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 9 | 3 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 20 | 0 | 20 |
| White | 8 | 0 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Nov 2020 to primary completion in Dec 2021, 12 months.
Results were first posted in Feb 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doravirine · Islatravir